+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Intravenous Iron Drugs Market Research Report by Product (Ferric Carboxymaltose, Iron Dextran, and Iron Sucrose), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5454933
  • Report
  • April 2022
  • Region: Global
  • 182 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Allergan, Inc.
  • Baxter International Inc
  • Galenica Ltd.
  • Novartis AG
  • Pharmacosmos A/S
The Global Intravenous Iron Drugs Market size was estimated at USD 2,413.84 million in 2021, USD 2,640.02 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.54% to reach USD 4,171.69 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Intravenous Iron Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Product, the market was studied across Ferric Carboxymaltose, Iron Dextran, and Iron Sucrose.
  • Based on Application, the market was studied across Cancer, Chronic Kidney Disease, and Inflammatory Bowel Disease.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Intravenous Iron Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Intravenous Iron Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Intravenous Iron Drugs Market, including Abbott Laboratories Inc, Actavis, Inc., Allergan, Inc., AMAG Pharmaceuticals. Inc., American Regent. Inc., Baxter International Inc, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Fresenius Medical Care AG & Co., Galenica Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., Rockwell Medical, Inc., Sanofi AG, Shield Therapeutics PLC, and Vifor Pharma Management Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Intravenous Iron Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Intravenous Iron Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Intravenous Iron Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Intravenous Iron Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Intravenous Iron Drugs Market?
6. What is the market share of the leading vendors in the Global Intravenous Iron Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Intravenous Iron Drugs Market?
Frequently Asked Questions about the Global Intravenous Iron Drugs Market

What is the estimated value of the Global Intravenous Iron Drugs Market?

The Global Intravenous Iron Drugs Market was estimated to be valued at $2413.8 Million in 2021.

What is the growth rate of the Global Intravenous Iron Drugs Market?

The growth rate of the Global Intravenous Iron Drugs Market is 9.5%, with an estimated value of $4171.7 Million by 2027.

What is the forecasted size of the Global Intravenous Iron Drugs Market?

The Global Intravenous Iron Drugs Market is estimated to be worth $4171.7 Million by 2027.

Who are the key companies in the Global Intravenous Iron Drugs Market?

Key companies in the Global Intravenous Iron Drugs Market include Abbott Laboratories Inc, Actavis, Inc., Allergan, Inc., AMAG Pharmaceuticals. Inc., American Regent. Inc., Baxter International Inc, Bayer AG, Bristol and Daiichi Sankyo Company, Ltd..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Allergan, Inc.
  • Baxter International Inc
  • Galenica Ltd.
  • Novartis AG
  • Pharmacosmos A/S

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic kidney disease and increasing number of patients undergoing dialysis
5.1.1.2. Rising geriatric population has led to improved functional capacity, increased hemoglobin levels
5.1.1.3. Growing number of diabetic patients
5.1.2. Restraints
5.1.2.1. Stringent regulations with the drug approval process
5.1.3. Opportunities
5.1.3.1. Need for preventing anemia in pregnant women as well as improving maternal and birth outcomes
5.1.3.2. Awareness towards healthcare & personal care
5.1.3.3. Investment in the healthcare sector, higher spending on medicine
5.1.4. Challenges
5.1.4.1. Side-effects related to these drugs
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Intravenous Iron Drugs Market, by Product
6.1. Introduction
6.2. Ferric Carboxymaltose
6.3. Iron Dextran
6.4. Iron Sucrose
7. Intravenous Iron Drugs Market, by Application
7.1. Introduction
7.2. Cancer
7.3. Chronic Kidney Disease
7.4. Inflammatory Bowel Disease
8. Americas Intravenous Iron Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Intravenous Iron Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Intravenous Iron Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories Inc
12.2. Actavis, Inc.
12.3. Allergan, Inc.
12.4. AMAG Pharmaceuticals. Inc.
12.5. American Regent. Inc.
12.6. Baxter International Inc
12.7. Bayer AG
12.8. Bristol-Myers Squibb Company
12.9. Daiichi Sankyo Company, Ltd.
12.10. Fresenius Medical Care AG & Co.
12.11. Galenica Ltd.
12.12. Merck & Co., Inc.
12.13. Novartis AG
12.14. Pfizer, Inc.
12.15. Pharmacosmos A/S
12.16. Rockwell Medical Technologies, Inc.
12.17. Rockwell Medical, Inc.
12.18. Sanofi AG
12.19. Shield Therapeutics PLC
12.20. Vifor Pharma Management Ltd.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL INTRAVENOUS IRON DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2027
FIGURE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 12. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2027
FIGURE 14. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, 2019-2027 (USD MILLION)
FIGURE 15. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 16. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2019-2027 (USD MILLION)
FIGURE 17. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 18. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 21. ARGENTINA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 22. BRAZIL INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 23. CANADA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 24. MEXICO INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 26. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 27. AUSTRALIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 28. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 29. INDIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 30. INDONESIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. JAPAN INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 32. MALAYSIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. PHILIPPINES INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. SINGAPORE INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. SOUTH KOREA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. TAIWAN INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. THAILAND INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. FRANCE INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. GERMANY INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. ITALY INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. NETHERLANDS INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. QATAR INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. RUSSIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. SAUDI ARABIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. SOUTH AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. SPAIN INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. UNITED ARAB EMIRATES INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. UNITED KINGDOM INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. GLOBAL INTRAVENOUS IRON DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 51. GLOBAL INTRAVENOUS IRON DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 52. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL INTRAVENOUS IRON DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL INTRAVENOUS IRON DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 20. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 21. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 22. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 23. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2019-2027 (USD MILLION)
TABLE 26. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY STATE, 2019-2027 (USD MILLION)
TABLE 28. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 36. ARGENTINA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 37. BRAZIL INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 38. CANADA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 39. MEXICO INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 40. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 41. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 42. AUSTRALIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 43. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 44. INDIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 45. INDONESIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 46. JAPAN INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 47. MALAYSIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 48. PHILIPPINES INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 49. SINGAPORE INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 50. SOUTH KOREA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 51. TAIWAN INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 52. THAILAND INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 54. FRANCE INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 55. GERMANY INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 56. ITALY INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. NETHERLANDS INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 58. QATAR INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 59. RUSSIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. SAUDI ARABIA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 61. SOUTH AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. SPAIN INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. UNITED ARAB EMIRATES INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. UNITED KINGDOM INTRAVENOUS IRON DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. GLOBAL INTRAVENOUS IRON DRUGS MARKET: SCORES
TABLE 66. GLOBAL INTRAVENOUS IRON DRUGS MARKET: BUSINESS STRATEGY
TABLE 67. GLOBAL INTRAVENOUS IRON DRUGS MARKET: PRODUCT SATISFACTION
TABLE 68. GLOBAL INTRAVENOUS IRON DRUGS MARKET: RANKING
TABLE 69. GLOBAL INTRAVENOUS IRON DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 70. GLOBAL INTRAVENOUS IRON DRUGS MARKET: MERGER & ACQUISITION
TABLE 71. GLOBAL INTRAVENOUS IRON DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 72. GLOBAL INTRAVENOUS IRON DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 73. GLOBAL INTRAVENOUS IRON DRUGS MARKET: INVESTMENT & FUNDING
TABLE 74. GLOBAL INTRAVENOUS IRON DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 75. GLOBAL INTRAVENOUS IRON DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories Inc
  • Actavis, Inc.
  • Allergan, Inc.
  • AMAG Pharmaceuticals. Inc.
  • American Regent. Inc.
  • Baxter International Inc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Ltd.
  • Fresenius Medical Care AG & Co.
  • Galenica Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmacosmos A/S
  • Rockwell Medical Technologies, Inc.
  • Rockwell Medical, Inc.
  • Sanofi AG
  • Shield Therapeutics PLC
  • Vifor Pharma Management Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...